Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 6th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 6th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 24th 2016

Risk-Based Contracting in Oncology

November 24th 2016

Benefits of a Medical Home Model in Oncology

November 24th 2016

Population Health and APMs

November 24th 2016

Is the Oncology Care Model Patient Centered?

November 24th 2016

Value-Based Care and APMs in Oncology: A Payer Perspective

November 24th 2016

Adapting and Paying for Value-Based Care

November 24th 2016

Defining Alternative Payment Models

November 23rd 2016

Another Death Reported in Juno's CAR-T Trial in Patients With ALL

AJMC Staff

Within 4 months of the last reported incident, Juno Therapeutics has again halted the phase 2 “Rocket” trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

November 23rd 2016

5 Key Highlights From the Patient-Centered Oncology Care Meeting

Surabhi Dangi-Garimella, PhD

Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology CareÂ® meeting had in store for its attendees.

November 23rd 2016

Dr Robert Carlson Predicts 2017 Will Be "Year of Uncertainty" For Healthcare

There is significant uncertainty surrounding the healthcare system’s future in 2017 under a Republican Congress and President, but it’s unlikely that the Affordable Care Act will be repealed without some replacement that accommodates the individuals newly covered by it, said Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network.

November 23rd 2016

PCOC16: Panel Discussion on the Future of Oncology Care

The 5th Annual Patient-Centered Oncology Care Meeting closed out with a panel discussion with an eye on the future. Donald Trump's surprise election has caused turmoil in the healthcare industry as the Affordable Care Act seems certain to be repealed at least in part. However, the move to value-based care will likely continue as planned.

November 23rd 2016

This Week in Managed Care: November 23, 2016

This week, the top managed care stories included the FDA's approval of rival combination therapies for type 2 diabetes, the American Medical Association issued mHealth guidelines, and a study found the dementia rate declining.

November 23rd 2016

Debra Madden: Oncologists Should Anticipate Patient Concerns About Immunotherapy

When helping cancer patients decide if immuno-oncology treatments are right for them, clinicians should not focus only on the potential risks and benefits, said Debra L. Madden, cancer research advocate and patient representative. Oncologists should ensure patients are aware of the variable responses to the therapy, like the phenomenon of pseudoprogression.

November 23rd 2016

PCOC16: Integrating Patient-Centered Outcomes in APMs

Surabhi Dangi-Garimella, PhD

At the 5th annual Patient-Centered Oncology CareÂ® meeting in Baltimore, Maryland, moderator Bruce Feinberg, DO, was joined by a care provider, a payer, and a community oncology representative to discuss efforts that maintain the patient at the core of payment models.

November 23rd 2016

Lung Cancer Screening Reveals How Deadly Smoking Is for Those With Diabetes

Mary Caffrey

While smoking has long been known to aggravate diabetes, the new study shows just how deadly the habit is for those with the chronic condition.

November 22nd 2016

PCOC16: "Oncology Care 2017" Panel Discusses Future of Cancer Care

Christina Mattina

The 5th annual Patient-Centered Oncology CareÂ® (PCOC) meeting, hosted by The American Journal of Managed Care, November 17-18, in Baltimore, Maryland, concluded with a panel discussion on the future of oncology care in 2017. The panelists concurred that value-based payment is here to stay despite the imminent changes in healthcare.

November 22nd 2016

PCOC16: Unraveling the Value in Oncology Care for the Payer

Surabhi Dangi-Garimella, PhD

At the 5th annual Patient-Centered Oncology CareÂ® meeting, Roy Beveridge, MD, senior vice president and chief medical officer at Humana, walked the audience through the healthcare world’s transition to value-based care and explained why payers have faith in this transition.

November 22nd 2016

Do We Need to Realign Evidence-Based Versus Precision Medicine?

Debra Madden

An interview with geneticist and pathologist Gabriel Bien-Willner, MD, PhD, FCAP, on why we need to change our outlook toward precision medicine in oncology.

November 21st 2016

Dr Roy Beveridge: Value-Based Care Brings Caregivers Together

Value-based care in oncology will be a great thing for patients because it will bring the caregivers together, said Roy Beveridge, MD, chief medical officer of Humana and the keynote speaker at Patient-Centered Oncology Care.

November 21st 2016

Catching Them Early: Outreach Program Could Avert HCC in Cirrhosis Patients

Surabhi Dangi-Garimella, PhD

A prospective trial that reached out to patients with cirrhosis to undergo an ultrasound screen found that the outreach effort doubled the percentage of patients who were screened for hepatocellular carcinoma.

November 21st 2016

Little Patient Benefit to Using G-CSF to Prevent Neutropenia

Laura Joszt, MA

There is little patient benefit to using granulocyte colony-stimulating factor (G-CSF) to help white blood cell growth and reduce the risk of infection in women with breast cancer, according to a study published in Journal of Clinical Oncology.

November 21st 2016

PCOC16: Immunoâ€Oncology Agents in a World of Precision Medicine

Surabhi Dangi-Garimella, PhD

At the 5th annual meeting of Patient-Centered Oncology CareÂ®, hosted by The American Journal of Managed Care, November 17-18 in Baltimore, Maryland, experts with diverse experiences and backgrounds discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

November 20th 2016

End of ACA Won't Stop March Toward Value-Based Care, Experts Say

President-elect Donald J. Trump’s upset win almost certainly means the end of the Affordable Care Act (ACA) as we know it, but experts who spoke at Patient-Centered Oncology Care Thursday and Friday said the movement toward value-based payment will continue. The fifth annual meeting, presented by The American Journal of Managed Care, took place in Baltimore, Maryland.

November 19th 2016

This Week in Managed Care: November 19, 2016

This week, the top managed care news included president-elect Donald Trump outlining parts of Obamacare he would be willing to keep, lawmakers confirming they still want to pass the 21st Century Cures Act, and the FDA held a 2-day hearing on off-label use.

November 19th 2016

Dr Bruce Feinberg: PCOC Has the Greatest Depth and Breadth

What makes Patient-Centered Oncology Care stand out from other meetings is the equal representation among all stakeholders, which gives the meeting a unique depth, said Bruce Feinberg, DO, vice president and chief medical officer at Cardinal Health Specialty Solutions.

November 18th 2016

Chronic Conditions May Be Barrier to Timely Cervical Cancer Screening

Christina Mattina

A survey examining nonfinancial barriers to cervical cancer screening indicated that women who were rarely or never screened were more likely to report having 1 or more chronic conditions. The study suggests that physicians include preventive services along with treatment for chronic conditions.

November 18th 2016

Sanofi Pasteur Announces It Will Discontinue Its Bladder Cancer Vaccine

AJMC Staff

Sanofi Pasteur has announced that it has decided to discontinue production of the BCG vaccine, which is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder.

November 17th 2016

ICU Admission Reduces Survival, Augments Costs Among Patients With AML

Surabhi Dangi-Garimella, PhD

A study published by researchers from the Fred Hutchinson Cancer Research Center in Seattle has found that admission to the intensive care unit reduced survival and increased the cost of care among patients undergoing treatment for acute myeloid leukemia.

November 17th 2016

Addressing the Psychosocial Needs in Older Breast Cancer Patients

Surabhi Dangi-Garimella, PhD

A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase.

November 16th 2016

First-in-Human Trial of CRISPR-Cas9 Begins in Lung Cancer Patients

Surabhi Dangi-Garimella, PhD

A hospital in China has made history by injecting a patient with lung cancer with revolutionary, yet controversial, CRISPR-Cas9—edited T cells. The first patient was injected on October 28.

...

88 89 90 91 92 93 94 95 96

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions